Guidance on Submission of CV



CURRICULUM VITAE

|Name: |

|James Robert Bonham |

|Present appointment: |

|National Newborn Screening laboratory lead – Public Health England |

|Address: |

|Clinical Chemistry |

|Sheffield Children’s NHS FT |

|Sheffield |

|S10 2TH |

|Telephone number: |Email address: |

|0114 3053831 |j.bonham@ |

|Qualifications: |

|BSc, MSc, PhD, FRCPath, CSci. |

|Professional registration: |

|HPC Reg no: CS03287 |

|Previous and other appointments: |

|National Laboratory Lead, Newborn Screening, UK National Programme Centre, Public Health England, April 2014 – to present |

|Clinical Director – Pathology, Genetics and Pharmacy 1992 - 2019 |

|Head of Department Clinical Chemistry, 1992 – 2016 |

|Sheffield Children’s Hospital R&D Director, 2006 – 2012 |

|Hon Chair of Inherited Metabolic Disease, University of Sheffield, 2012 - present |

|Professional activities: |

|President, ISNS 2019 - present |

|Vice President, ISNS, 2017 - 2019 |

|Chair, Scientific Advisory Board, ERNDIM, EU EQA provider, 2007-2013 |

|Treasurer, Society for the Study of Inborn Errors of Metabolism, 1995 – 2000 and 2008 - 2012 |

|Chair, UK Newborn Screening Laboratory Network, 2008-2014 |

|Chair, MetBioNet, UK Inherited Metabolic Disease Network, 2008 – 2016 |

|Examiner, Royal College of Pathologists, 2008 – 2015 |

|RCPath representative, Clinical Reference Group for Inherited Metabolic Disorders, 2012 – 2016 |

|Scheme Advisor, ERNDIM, EU EQA provider, 1993 - present |

|Consultant to the British Standards Institute, 2014 – present |

|UK Accreditation Service assessor for Medical Laboratories, 2016 - present |

|Advisor to overseas development projects relating to newborn screening in India, Bangladesh, China, Iran and Iraq, 2012 - present |

|Research experience: |

|Sheffield Children’s Hospital, R&D Director |

| |

|Projects: |

|Collaboration for Leadership in Applied Health Research and Care – SY. 2008 – 2013 Genetics theme lead. An NIHR funded project |

|>£1.0m, to conduct a pilot to evaluate expanded newborn screening in the UK. This multicentre project, led by Prof Bonham was |

|successful in recruiting more than 400k patients and resulted in a change in national policy to amend the conditions included within the |

|national programme. |

|Collaboration for Leadership in Applied Health Research and Care – SY. 2014 – 2018 Rare Disease lead. An NIHR funded project £130k |

|to design and evaluate telehealth and IT as means of supporting families within the newborn screening programme. This project is in the|

|design phase but has attracted a number of commercial partners. Prof Bonham is the project lead. |

|Safer Hospitals Health Technology Fund 2014. £100k to explore and design safe and effective digital means of messaging newborn |

|screening results. This project has been successful and is nearing completion. It is likely that the project will improve patient |

|safety and reduce costs by an estimated £3.0m annually. Prof Bonham is the project lead. |

|HICF/NIHR Next generation sequencing as an adjunct/alternative for newborn screening. £850k – three year project begun 2015. Prof |

|Bonham is a co-applicant |

|Research training: GCP training - current |

|Publications: |

|No |

|Reference |

| |

|1 |

| |

| |

| |

| |

|2 |

| |

| |

| |

|3 |

| |

| |

|Carling RS, Burden D, Hutton F, Randle R, John K and Bonham JR (2018) Introduction of a Simple Second Tier Screening Test for C5 Isobars |

|in Dried Blood Spots: Reducing the False Positive Rate for Isovaleric Acidaemia in Expanded Newborn Screening. |

|JIMD Rep. 2018;38:75-80. doi: 10.1007/8904_2017_33. Epub 2017 Jun 20. |

|Moody L, Atkinson L, Kehal I, Bonham JR.(2017) |

|Healthcare professionals' and parents' experiences of the confirmatory testing period: a qualitative study of the UK expanded newborn |

|screening pilot. |

|BMC Pediatr. 2017 May 8;17(1):121. doi: 10.1186/s12887-017-0873-1. |

|Peters V, Bonham JR, Hoffmann GF, Scott C, Langhans CD (2016). Qualitative urinary organic acid analysis: 10 years of quality |

|assurance. J Inherit Metab Dis. 2016 May 4 |

| |

|4 |

|Hart AR, Bonham J, Yap S (2015) Early developmental outcome in GA1 following diagnosis on newborn screening. JIMD 38 Suppl 1 |

| |

|5 |

|JM, Clark S, Dalley J Hind J Croft, J, Colyer S, Manning N, Scott C, Kirk R, Bonham J, Downing M, Yap S Glamunzina E, Sharrard M (2015) |

|Fatty acid oxidation flux data from 304 symptomatic patients diagnosed with a range of fatty acid oxidation disorders facilitates the |

|prediction of phenotype in screen positive babies from Newborn Screening programmes JIMD 38 Suppl 1 |

| |

|6 |

|Peters V, Bonham J, Hoffmann G, Scott C, Langhans CD (2015) Qualitative urinary organic acid analysis: 10 years of quality control JIMD |

|38 Suppl 1 |

| |

|7 |

|Moorthie S, Cameron L, Sagoo GS, Bonham JR, Burton H (2014) Systematic review and meta-analysis to estimate the birth prevalence of five |

|inherited metabolic diseases J Inher Metab Dis July 2014 |

| |

|8 |

|Bonham JR (2014) Expanded Newborn Screening – progress into practice Clinical Biochemistry 47 697 – 698 |

| |

|9 |

|Bonham JR (2014) The organisation of training for laboratory scientists in inherited metabolic disease, newborn screening and paediatric |

|clinical chemistry Clinical Biochemistry 47:763-764 |

| |

|10 |

|Bonham JR (2013) Impact of new screening technologies: should we screen and does phenotype influence this decision? J Inherit Metab |

|Dis. 2013 Jul;36(4):681-6 |

| |

|11 |

|Coffey AJ et al (2013) A genetic study of Wilson's disease in the United Kingdom. Brain. 2013 May;136(Pt 5):1476-87 |

| |

|12 |

|Marquardt G et al (2012) Enhanced interpretation of newborn screening results without analyte cutoff values. Genet in Med |

|2012(7);14:648-655. |

| |

|13 |

|Dixon S, Shackley P, Bonham J Ibbotson R (2012) Putting a value on the avoidance of false positive results when screening for inherited|

|metabolic disease in the newborn. J Inher Metab Dis 35 (1) 169-76 |

| |

|14 |

|Ong et al (2012) Randomized clinical trial of glutamine-supplemented versus standard parenteral nutrition in infants with surgical |

|gastrointestinal disease. Br J Surg. 2012 Jul;99(7):929-38. doi: 10.1002/bjs.8750. Epub 2012 Apr 19 |

| |

|15 |

|McHugh DM et al (2011) Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass |

|spectrometry: a worldwide collaborative project. Genet Med 13:230-254 |

| |

|16 |

|Shakespeare L, Downing M, Allen J, Casbolt AM Ellin S, Maloney M, Race G, Bonham J (2010) Elevated phenylalanine on newborn screening: |

|follow-up testing may reveal undiagnosed galactosaemia. Ann Clin Biochem 47: 567-69 |

| |

|17 |

|Connelly PJ, Prentice NP, Cousland G, Bonham J (2008) A randomised double-blind placebo-controlled trial of folic acid supplementation of|

|cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry. 2008 Feb;23(2):155-60 |

| |

|18 |

|Sharrard MJ, Downing M, Manning NJ, Olpin SE, Clark S, Matthews AJ, Bonham JR Outcome of an elevated C8 from Newborn Screening in those |

|not affected by MCADD J.Inhet.Metab.Dis. (2008) 31 Suppl 1 p33 128-P |

| |

|19 |

|Lang TF, Parr JR, Matthews EE, Gray RGF, Bonham JR, Kay JDS (2008) Practical difficulties in the diagnosis of transient non-ketotic |

|hyperglycinaemia Dev Med Child Neurol. 2008 Feb;50(2):157-9 |

| |

|20 |

|Peters V, Garbade SE, Langhans CD, Hoffmann GF, Pollitt RJ, Downing M, Bonham JR (2008) Qualitative urinary organic acid analysis: |

|methodological approaches and performance. JIMD 31(6) 690-6 |

| |

|21 |

|Olpin SE, Clark S, Ghoni F, Talbot R, Manning N, Downing M, Bonham J, Allen J, John K, Croft J, Smith E, Cohen M. The investigation of |

|metabolic disease in post mortem samples. J Inher Metab Dis (2007) 30 suppl 1 194-P; 49. |

| |

|22 |

|Sharrard MJ, Downing M, Clark s, Olpin SE, Manning NJ, Durkie M, Watkinson J, Bonham JR. (2008) Clinically presenting fatty acid |

|oxidation defect with a medium chain acyl-CoA dehydrogenase deficiency (MCADD) biochemical phenotype and normal dried blood spot octanoyl|

|carnitine (C8), not detected by newborn screening. J.Inhet.Metab.Dis. 31 Suppl 1 p33 128-P |

| |

|23 |

|Hart CE, Race V, Achouri Y, Wiame E, Sharrard M, Olpin SE, Watkinson J, Bonham JR, Jaeken J, Matthijs G, Van Schaftingen E. (2007) |

|Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am J Hum Genet. 2007 May;80(5):931-7 |

| |

|24 |

|Bowker R, Green A, Bonham JR (2007) Guidelines for the investigation and management of a reduced level of consciousness in children: |

|implications for clinical biochemistry laboratories 2007 Ann Clin Biochem 44: 506-11 |

| |

|25 |

|Mordekar SR, Guthrie P, Bonham JR, Olpin SE, Hargreaves I, Baxter PS. (2006) The significance of reduced respiratory chain enzyme |

|activities: clinical, biochemical and radiological associations. Eur J Paediatr Neurol. 2006 Mar;10(2):78-82 |

| |

|26 |

|Olpin SE, Clark S, Andresen BS, Bischoff C, Olsen RK, Gregersen N, Chakrapani A, Downing M, Manning NJ, Sharrard M, Bonham JR, Muntoni F,|

|Turnbull DN, Pourfarzam M. (2005) Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein |

|deficiency. J Inherit Metab Dis. 2005;28(4):533-44 |

| |

|27 |

|Moat SJ, Bao L, Fowler B, Bonham JR, Walter JH, Kraus JP (2004) The molecular basis of cystathionine beta-synthase (CBS) deficiency in UK|

|and US patients with homocystinuria. Hum Mutat. Feb;23(2):206 |

| |

|28 |

|Bonham JR, Downing M, Dalton A (2003) Screening for cystic fibrosis: the practice and the debate. Eur J Pediatr. Dec;162 Suppl 1:S42-5 |

| |

|29 |

|Gabra HO, Fenton PA, Bonham JR, Mackinnon AE (2003) Hyperammonemia with complex urinary tract anomaly: a case report. J Pediatr Surg. |

|Nov;38(11):E16-7 |

| |

|30 |

|Olpin SE, Afifi A, Clark S, Manning NJ, Bonham JR, Dalton A, Leonard JV, Land JM, Andresen BS, Morris AA, Muntoni F, Turnbull D, |

|Pourfarzam M, Rahman S, Pollitt RJ (2003) Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) |

|deficiency. J Inherit Metab Dis. 2003;26(6):543-57 |

| |

|31 |

|Carragher FM, Bonham JR, Smith JM (2003) Pitfalls in the measurement of some intermediary metabolites. Ann Clin Biochem. 2003 Jul;40(Pt |

|4):313-20 |

| |

|32 |

|Matthews A, Johnson TN, Rostami-Hodjegan A, Chakrapani A, Wraith JE, Moat SJ, Bonham JR, Tucker GT (2002) An indirect response model of |

|homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. Br J Clin Pharmacol. 2002 |

|Aug;54(2):140-6 |

| |

|33 |

|Pullin CH, Bonham JR, McDowell IF, Lee PJ, Powers HJ, Wilson JF, Lewis MJ, Moat SJ. (2001) Vitamin C therapy ameliorates vascular |

|endothelial dysfunction in treated patients with Homocystinuria. J Inherit Metab Dis 2002 May;25(2):107-18 |

| |

|34 |

|Davis KR, Pearson H, Moat S, Bonham JR, Donnelly R (2001) Acute hyperhomocysteinaemia affects pulse pressure but not microvascular |

|vasodilator function. Br J Clin Pharmacol. 2001 Sep;52(3):327-32. |

| |

|35 |

|Olpin SE, Allen J, Bonham JR, Clark S, Clayton PT, Calvin J, Downing M, Ives K, Jones S, Manning NJ, Pollitt RJ, Standing SJ, Tanner MS |

|(2001). Features of carnitine palmitoyltransferase type I deficiency. J Inherit Metab Dis. Feb;24(1):35-42. |

| |

|36 |

|Gale CR, Ashurst H, Phillips NJ, Moat SJ, Bonham JR, Martyn CN (2001). Renal function, plasma homocysteine and carotid atherosclerosis |

|in elderly people. Atherosclerosis. Jan;154(1):141-6. |

| |

|37 |

|Moat SJ, Bonham JR, Powers HJ (2001). Role of aminothiols as a component of the plasma antioxidant system and relevance to |

|homocysteine-mediated vascular disease. Clin Sci (Lond). Jan;100(1):73-9. |

| |

|38 |

|Moat SJ, Bonham JR, Cragg RA, Powers HJ (2000). Elevated plasma homocysteine elicits an increase in antioxidant enzyme activity. Free |

|Radic Res. Feb;32(2):171-9. |

| |

|39 |

|Yanai S, Baxter P, Rittey C, Guthrie P, Bonham J, Tanner S, Heales S (1999). Clinical and laboratory findings in referrals for |

|mitochondrial DNA analysis. Arch Dis Child. Nov;81(5):460. No abstract available. |

| |

|40 |

|Olpin SE, Manning NJ, Pollitt RJ, Bonham JR, Downing M, Clark S (1999). |

|The use of [9,10-3H]myristate, [9,10-3H]palmitate and [9,10-3H]oleate for the detection and diagnosis of medium and long-chain fatty acid|

|oxidation disorders in intact cultured fibroblasts. Adv Exp Med Biol. ;466:321-5. |

| |

|41 |

|Crofts DJ, Michel VJ, Rigby AS, Tanner MS, Hall DM, Bonham JR (1999). Assessment of stool colour in community management of prolonged |

|jaundice in infancy. Acta Paediatr. Sep;88(9):969-74. |

| |

|42 |

|Downing M, Allen JC, Bonham JR, Edwards RG, Manning NJ, Olpin SE, Pollitt RJ (1999). Problems in the detection of fatty acid oxidation |

|defects: experience of a quality assurance programme for qualitative urinary organic acid analysis. J Inherit Metab Dis. |

|May;22(3):289-92. |

| |

|43 |

|Moat SJ, Bonham JR, Allen JC, Powers HJ, McDowell IF (1999). Decreased circulating plasma lipids in patients with homocystinuria. J |

|Inherit Metab Dis. May;22(3):243-6 |

| |

|44 |

|Moat SJ, Bonham JR, Tanner MS, Allen JC, Powers HJ (1999). Recommended approaches for the laboratory measurement of homocysteine in the |

|diagnosis and monitoring of patients with hyperhomocysteinaemia. Ann Clin Biochem. May;36 ( Pt 3):372-9.. |

| |

|45 |

|Bonham JR, Guthrie P, Downing M, Allen JC, Tanner MS, Sharrard M, Rittey C, Land JM, Fensom A, O'Neill D, Duley JA, Fairbanks LD (1999). |

|The allopurinol load test lacks specificity for primary urea cycle defects but may indicate unrecognised mitochondrial disease. J |

|Inherit Metab Dis. Apr;22(2):174-84. |

| |

|46 |

|Manning NJ, Bonham JR, Downing M, Edwards RG, Olpin SE, Pollitt RJ, Pourfarzam M, Sharrard MJ, Tanner MS (1999). Normal acylcarnitines |

|in maternal urine during a pregnancy affected by glutaric aciduria type II. J Inherit Metab Dis. Feb;22(1):88-9. |

| |

|47 |

|Martland T, Mbamali AC, Rittey C, Tanner S, Bonham JR, Griffiths PD. Ornithine transcarbamylase deficiency: a case report (1998). |

|Neuropediatrics. Dec;29(6):331-2. |

| |

|48 |

|Delves HT, Sieniawska CE, Fell GS, Lyon TD, Dezateux C, Cullen A, Variend S, Bonham JR, Chantler SM (1997). Determination of antimony in|

|urine, blood and serum and in liver and lung tissues of infants by inductively coupled plasma mass spectrometry. Analyst. |

|Nov;122(11):1323-9. |

| |

|49 |

|Olpin SE, Bonham JR, Downing M, Manning NJ, Pollitt RJ, Sharrard MJ, Tanner MS (1997). Carnitine-acylcarnitine translocase deficiency--a|

|mild phenotype. J Inherit Metab Dis. Sep;20(5):714-5. |

| |

|50 |

|Green A, Sewell I, MacKenzie F, Downing M, Bonham JR (1995) Laboratory quality assurance for inherited metabolic disorders in the United |

|Kingdom. Exerpta Medica Proceedings of 8th International Symposium on Quality Control, Kobe, June 17-18, 1995 "Quality Control in the |

|Clinical Laboratory '95" : 228 - 240. |

| |

|51 |

|Baker A, Gormally S, Saxena R, Baldwin D, Drumm B, Bonham J, Portmann B, Mowatt AP (1995) Copper-associated liver disease in childhood. J|

|Hepatol 23(5) : 538-43 |

| |

|52 |

|Bonham JR, Downing M, Pollitt RJ, Manning NJ, Carpenter KH, Olpin SE, Allen JC, Worthy E. (1994) Quality assessment of urinary organic |

|acid analysis. Ann Clin Biochem 31 (pt2): 129-33. |

| |

|53 |

|Kahler SG, Sherwood WG, Woolf D, Lawless ST, Zariitsky A, Bonham JR, Taylor CJ, Clarke JT, Durie P, Leonard JV. (1994) Pancreatitis in |

|patients with organic acidemias. J Pediatr 124(2): 239-43. |

| |

|54 |

|Taylor CJ, Olpin S, Rattenbury J, Whippey A, Lunt C, Beckles-Wilson N, Higginbottom J, Pollitt RJ, Bonham JR,Taitz LS. (1993) Familial |

|hypercholesterolaemia: pilot study to identify children at risk. Journal of Clinical Pathology 46(8):730-3. |

| |

|55 |

|Bonham JR. (1993) The investigation of hypoglycaemia during childhood. Ann Clin Biochem 30 (pt3): 328-47. |

| |

|56 |

|Carpenter KH, Worthy E, Variend S Bonham J (1993) Viterous humour and cerebrospinal fluid hypoxanthine concentration as a marker of |

|pre-mortem hypoxia in SIDS. Journal of Clinical Pathology 46(7):650-3. |

| |

|57 |

|Bonham JR. Downing M (1992). Metabolic deficiencies and SIDS. Journal of Clinical Pathology 45(11 Suppl): 33-8. |

| |

|58 |

|Bonham JR, Meeks A, Levin M, Gibson A, Hawkins K, Gerrard M (1992) Complete recovery from hemorrhagic shock and encephalopathy (see |

|comments). 120 (3):440-3 |

| |

|59 |

|Xuereb JH, Peery RH, Candy JM, Perry EK, Marshall E, Bonham JR (1991) Nerve cell loss in the thalamus in Alzheimers's disease and |

|Parkinson's disease. Brain 114 (Pt 3): 1363-79 |

| |

|60 |

|Xuereb JH, Candy JM, Perry EK, Marshall E, Bonham JR (1990) Distribution of neurofibrillary tangle formation and (3H)-D-asparate |

|receptior binding in the thalmuis in the normal elderly brain, in Alzheimer's disease and in Parkinson's disease. Neuropathol Appl |

|Neurobiol 16(6): 477-88 |

| |

|61 |

|Xuereb JH, Perry EK, Candy JM, Bonham JR, Perry RH, Marshall E (1990) Parameters of cholinergic neurotransmission in the thalamus in |

|Parkinson's disease and Alzhiemer's disease. Journal of Neurological Science 99(2-3): 185-97. |

| |

|62 |

|Carpenter KH, Bonham JR, Clarke A (1990) Rett's Syndrome and othinine carbamoyltransferase deficiency. Journal of Inherited Metabolic |

|Disease 13(3): 308-10 |

| |

|63 |

|Clarke A, Garnder-Medwin D, Richardson J, McGann A, Bonham JR, Carpenter KH, Bhattacharya S, Haggerty D, Fleetwood JA, Anynsley Green A |

|(1990) Abnormalities of carbohydrate metabolism an of OTC gene function in the Rett syndrome. Brain Dev. 12(1) 119-24. |

| |

|64 |

|Rattenbury JR, Bonham JR, Allen JC, Meeks A (1990) Appearance of vigabatrin (gamma vinyl-gamma-aminobutyric acid, 4-amino-hex-5-enoic |

|acid) in screening tests and analyis for amino acids. Clin Chem 36(1): 159-60. |

|J Inher Metab Dis (2007) 30 suppl 1 002-P ;1. |

| |

|65 |

|Bonham JR, Stephenson TJ, Carpenter KH, Rattenbury JM, Cromby CH, Pollitt RJ, Hull D (1990) D(+) -glyceric aciduria: etiology and |

|clinical consequences. Pediatr Res 28 (1): 38-41. |

| |

|66 |

|Perry EK, Smith CJ, Bonham JR, Rodway M, Court J, Dale G Interaction of tetrahydroaminoacridine (THA) with human cortical nicotinic and |

|muscarinic receptor binding in vitro. Neurosci Lett 1988;91:211-16. |

| |

|67 |

|Smith CJ, Perry EK, Perry RH, Candy JM, Johnson M, Dick DJ, Bonham JR, Fairburn A, Blessed G, Birdsall NJM Muscarinic cholinergic |

|receptor subtypes in hippocampus in human cognitive disorders. J Neurochem 1988;50:847-56. |

| |

|68 |

|Bonham JR Dale G, Atack JR, Scott DJ, Wagget J The characterisation of molecular forms of acetylcholinesterase in the aganglionic rectal |

|tissue of patients with Hirschsprung’s disease. Clin Chim Acta 1987;171:263-70. |

| |

|69 |

|Bonham JR, Dale G, Atack JR Neural tube defect specific acetylcholinesterase : Its properties and its measurement in the detection of |

|anencephaly and spina bifida. Clin Chim Acta 1987;171:69-78. |

| |

|70 |

|Atack JR, Perry EK, Bonham JR, Boakes R, Candy JM. Loss and recovery of AChE molecular forms in the fornix-lesioned rat hippocampus. |

|Neurosci Lett 1987;79:179-84. |

| |

|71 |

|Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH Molecular forms of BchE in human neocortex during development and degeneration of the |

|cortical cholinergic system. J Neurochem 1987;48:1687-92. |

| |

|72 |

|Atack JR, Perry EK, Bonham JR, Perry RH Molecular forms of AChE and BChE in plasma and CSF. J Neurochem 1987;48:1845-50. |

| |

|73 |

|Bonham JR, Dale G, Scott D, Wagget J A 7-year study of the diagnostic value of rectal mucosal acetylcholinesterase measurement in |

|Hirschsprung’s disease. J Ped Surg 1987;22:150-52. |

| |

|74 |

|Perry EK, Perry RH, Smith CJ, Purohit D, Bonham JR, Dick DJ, Candy JM, Edwardson JA, Fairbairn JA. Cholinergic receptors in cognitive |

|disorders. Can J Neurol Sci 1986;13:521-27. |

| |

|75 |

|Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH Molecular forms of actylcholinesterase and butyrylcholinesterase in the aged human |

|central nervous system. J Neurochem 1986;47:263-67. |

| |

|76 |

|Bonham JR, Dale G, Scott D, Wagget Molecular forms of acetylcholinesterase in Hirschsprung’s disease. Clin Chim Acta 1985;145:297-305. |

| |

|77 |

|Bonham JR, Atack JR A neural tube defect specific form of acetylcholinesterase in amniotic fluid. Clin Chim Acta 1983;135:233-7. |

| |

|78 |

|Atack JR, Perry EK, Bonham JR, Perry RH, Tomlinson BE, Blessed G, Fairburn A. Molecular forms of AChE in senile dementia of Alzheimer |

|type : Selective loss of the intermediate (10S) form. Neurosci Lett 1983;40:100-4. |

| |

|79 |

|Bonham JR, Gowenlock AH, Timothy JAD Acetylcholinesterase and butyrylcholinesterase measurement in the prenatal detection of neural tube |

|defects and other fetal malformations. Clin Chim Acta 1981;115:163-70. |

| |

|80 |

|Dale G, Archibald A, Bonham JR, Lowden P Diagnosis of neural tube defects by estimation of amniotic fluid acetylcholinesterase. Brit J |

|Obs Gynaec 1981;115:163-70. |

| |

|81 |

|Dale G, Bonham JR, Lowden P, Rangecroft L, Wagget J, Scott DJ Diagnostic value of rectal mucosal acetylcholinesterase levels in |

|Hirschsprung's disease. Lancet 1979;(i):347-9. |

| |

|82 |

|Dale G, Bonham JR, Riley KWA, Wagget J An improved method for the determination of acetylcholinesterase activity in rectal biopsy tissue |

|from patients with Hirschsprung's disease. Clin Chim Acta 1977;77:407-13. |

| |

|Signature: |Date: |

|[pic] |2nd October 2019 |

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download